Related Experiment Video

Updated: Mar 30, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

3.3K

Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers

Alfonso Duenas-Gonzalez1, José L Medina-Franco2, Alma Chavez-Blanco3

  • 1a Instituto de Investigaciones Biomédicas , Universidad Nacional Autónoma de México/Instituto Nacional de Cancerología , Mexico City , Mexico.

Expert Opinion on Pharmacotherapy
|November 13, 2015
PubMed
Abstract

Insights

DNA methylation inhibitors show promise for treating gynecological cancers like cervical and ovarian cancers. Further clinical trials and epigenetic research are needed to optimize their use in cancer therapy.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • DNA methylation is a key epigenetic mechanism implicated in cancer development.
  • DNA methyltransferase inhibitors are emerging as a therapeutic strategy for various cancers.
  • Gynecological cancers, including cervical, ovarian, and endometrial carcinomas, are being investigated for their response to epigenetic therapies.

Purpose of the Study:

  • To review the current understanding of DNA methylation in gynecological cancers.
  • To discuss the role of DNA methylation as a therapeutic target in cervical, ovarian, and endometrial cancers.
  • To evaluate the efficacy of demethylating agents in clinical trials for gynecological malignancies.

Main Methods:

  • Comprehensive literature review of DNA methylation and cancer.
  • Analysis of current knowledge on DNA methylation in cervical, ovarian, and endometrial carcinomas.
  • Discussion of findings from recent clinical trials involving demethylating agents.

Main Results:

  • DNA methylation plays a significant role in the pathogenesis of gynecological cancers.
  • Early clinical trials of demethylating agents for cervical and ovarian cancers demonstrate promising outcomes.
  • Methylome analyses are crucial for identifying predictive biomarkers of treatment response and toxicity.

Conclusions:

  • DNA demethylating agents hold potential for treating gynecological cancers, with early results being encouraging.
  • Expanding clinical trials and integrating methylome analyses can accelerate therapeutic advancements.
  • Identifying cancer-specific epigenetic drivers is essential for developing targeted therapies in highly selected patient populations.
Keywords:
DNA methylationDNMT inhibitorscervical cancerendometrial cancerepigeneticsgynecologic cancerovarian cancer

More Related Videos

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

6.3K
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
43
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.3K